Andreas von Deimling

172.7k total citations · 16 hit papers
652 papers, 59.5k citations indexed

About

Andreas von Deimling is a scholar working on Genetics, Molecular Biology and Cancer Research. According to data from OpenAlex, Andreas von Deimling has authored 652 papers receiving a total of 59.5k indexed citations (citations by other indexed papers that have themselves been cited), including 322 papers in Genetics, 299 papers in Molecular Biology and 161 papers in Cancer Research. Recurrent topics in Andreas von Deimling's work include Glioma Diagnosis and Treatment (317 papers), Cancer Genomics and Diagnostics (70 papers) and Meningioma and schwannoma management (67 papers). Andreas von Deimling is often cited by papers focused on Glioma Diagnosis and Treatment (317 papers), Cancer Genomics and Diagnostics (70 papers) and Meningioma and schwannoma management (67 papers). Andreas von Deimling collaborates with scholars based in Germany, United States and France. Andreas von Deimling's co-authors include David N. Louis, Guido Reifenberger, Arie Perry, Otmar D. Wiestler, David W. Ellison, Paul Kleihues, Hiroko Ohgaki, Webster K. Cavenee, Dominique Figarella-Branger and Christian Hartmann and has published in prestigious journals such as Nature, Proceedings of the National Academy of Sciences and Journal of Clinical Investigation.

In The Last Decade

Andreas von Deimling

630 papers receiving 58.7k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary

2016 10.9k citations Arie Perry, Guido Reifenberger et al. profile →
The 2021 WHO Classification of Tumors of the Central Nervous System: a summary

2021 6.2k citations Arie Perry, Stefan M. Pfister et al. profile →
An endogenous tumour-promoting ligand of the human aryl hydrocarbon receptor

2011 1.4k citations Christiane A. Opitz, Felix Sahm et al. profile →
Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differentiation and age: a study of 1,010 diffuse gliomas

2009 868 citations Christian Hartmann, David Capper et al. profile →
Analysis of the IDH1 codon 132 mutation in brain tumors

2008 793 citations Wolf Mueller, Andrey Korshunov et al. profile →
Analysis of BRAF V600E mutation in 1,320 nervous system tumors reveals high mutation frequencies in pleomorphic xanthoastrocytoma, ganglioglioma and extra-cerebellar pilocytic astrocytoma

2011 739 citations David Capper, Christel Herold‐Mende et al. profile →
Gene expression-based classification of malignant gliomas correlates better with survival than histological classification.

2003 719 citations Christian Hartmann, Andreas von Deimling et al. profile →
Long-term survival with glioblastoma multiforme

2007 676 citations Dietmar Krex, Christian Hartmann et al. profile →
Patients with IDH1 wild type anaplastic astrocytomas exhibit worse prognosis than IDH1-mutated glioblastomas, and IDH1 mutation status accounts for the unfavorable prognostic effect of higher age: implications for classification of gliomas

2010 627 citations Christian Hartmann, Bettina Hentschel et al. profile →
Intracranial Thermotherapy using Magnetic Nanoparticles Combined with External Beam Radiotherapy: Results of a Feasibility Study on Patients with Glioblastoma Multiforme

2006 574 citations Andreas von Deimling et al. profile →
EANO guidelines for the diagnosis and treatment of meningiomas

2016 571 citations Andreas von Deimling, Michael Weller et al. profile →
NOA-04 Randomized Phase III Trial of Sequential Radiochemotherapy of Anaplastic Glioma With Procarbazine, Lomustine, and Vincristine or Temozolomide

2009 571 citations Wolfgang Wick, Christian Hartmann et al. Journal of Clinical Oncology profile →
cIMPACT-NOW update 3: recommended diagnostic criteria for “Diffuse astrocytic glioma, IDH-wildtype, with molecular features of glioblastoma, WHO grade IV”

2018 553 citations Kenneth Aldape, Arie Perry et al. profile →
Glioblastoma: pathology, molecular mechanisms and markers

2015 506 citations Kenneth Aldape, Guido Reifenberger et al. profile →
MGMT testing—the challenges for biomarker-based glioma treatment

2014 393 citations Wolfgang Wick, Michael Weller et al. profile →
cIMPACT-NOW update 5: recommended grading criteria and terminologies for IDH-mutant astrocytomas

2020 310 citations Kenneth Aldape, Arie Perry et al. profile →

Peers

Countries citing papers authored by Andreas von Deimling

Since Specialization

Citations

This map shows the geographic impact of Andreas von Deimling's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Andreas von Deimling with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Andreas von Deimling more than expected).

Fields of papers citing papers by Andreas von Deimling

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Andreas von Deimling. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Andreas von Deimling. The network helps show where Andreas von Deimling may publish in the future.

Co-authorship network of co-authors of Andreas von Deimling

This figure shows the co-authorship network connecting the top 25 collaborators of Andreas von Deimling. A scholar is included among the top collaborators of Andreas von Deimling based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Andreas von Deimling. Andreas von Deimling is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	The Epigenetic Landscape of Meningiomas 2023 ·Advances in experimental medicine and biology ·Justin Z. Wang, Farshad Nassiri, Kenneth Aldape, Andreas von Deimling, Felix Sahm	5
2	Integrative analysis reveals early and distinct genetic and epigenetic changes in intraductal papillary and tubulopapillary cholangiocarcinogenesis 2021 ·Gut ·Benjamin Goeppert, Damian Stichel, Réka Tóth, (unknown), (unknown), Anna Melissa Schlitter, Olaf Neumann, Yassen Assenov, Monika Vogel, Arianeb Mehrabi, Katrin Hoffmann, Bruno Köhler, Christoph Springfeld, Dieter Weichenhan, Christoph Plass, Iréne Esposito, Peter Schirmacher, Andreas von Deimling, Stéphanie Roessler	33
3	Surfactant Expression Defines an Inflamed Subtype of Lung Adenocarcinoma Brain Metastases that Correlates with Prolonged Survival 2020 ·Clinical Cancer Research ·(unknown), Andreas Möck, Carmen Rapp, Steffen Dettling, Rolf Warta, Christoph Geisenberger, Christine Jungk, Leila R. Martins, Niels Grabe, David Reuß, Jürgen Debus, Andreas von Deimling, Amir Abdollahi, Andreas Unterberg, Christel Herold‐Mende	23
4	DNA Methylation Profiling Identifies Distinct Clusters in Angiosarcomas 2019 ·Clinical Cancer Research ·Marije E. Weidema, (unknown), Christian Koelsche, Ingrid M.E. Desar, Patrick Kemmeren, Melissa H.S. Hillebrandt-Roeffen, Vincent K.Y. Ho, Winette T.A. van der Graaf, Yvonne M.H. Versleijen‐Jonkers, Andreas von Deimling, Uta Flucke	32
5	Mutant IDH Sensitizes Gliomas to Endoplasmic Reticulum Stress and Triggers Apoptosis via miR-183-Mediated Inhibition of Semaphorin 3E 2019 ·Cancer Research ·Ying Zhang, Stefan Pusch, (unknown), (unknown), Matthew J. Ellis, Joanne Lau, (unknown), (unknown), Francesca Launchbury, Angela Richard-Loendt, Jasper de Boer, Sheng Chen, Lei Wang, Andreas von Deimling, Ningning Li, Sebastian Brandner	28
6	Identification of CRKII, CFL1, CNTN1, NME2, and TKT as Novel and Frequent T-Cell Targets in Human IDH-Mutant Glioma 2018 ·Clinical Cancer Research ·Steffen Dettling, Slava Stamova, Rolf Warta, Martina Schnölzer, Carmen Rapp, Anchana Rathinasamy, David Reuß, (unknown), Saskia Roesch, Christine Jungk, Uwe Warnken, Volker Eckstein, Niels Grabe, Christoph Schramm, Markus Weigand, Andreas von Deimling, Andreas Unterberg, Philipp Beckhove, Christel Herold‐Mende	22
7	A Phase II, Randomized, Study of Weekly APG101+Reirradiation versus Reirradiation in Progressive Glioblastoma 2014 ·Clinical Cancer Research ·Wolfgang Wick, Harald Fricke, Klaus Junge, (unknown), Tobias Martens, Oliver Heese, Benedikt Wiestler, Maximilian G. Schliesser, Andreas von Deimling, Josef Pichler, (unknown), Inga Harting, Jürgen Debus, Christian Hartmann, (unknown), Michael Platten, Martin Bendszus, Stephanie E. Combs	95
8	The Endogenous Tryptophan Metabolite and NAD+ Precursor Quinolinic Acid Confers Resistance of Gliomas to Oxidative Stress 2013 ·Cancer Research ·Felix Sahm, Iris Oezen, Christiane A. Opitz, Bernhard Radlwimmer, Andreas von Deimling, Tilman Ahrendt, Seray Adams, Helge B. Bode, Gilles J. Guillemin, Wolfgang Wick, Michael Platten	131
9	Targeting the BRAF V600E Mutation in Multiple Myeloma 2013 ·Cancer Discovery ·Mindaugas Andrulis, Nicola Lehners, David Capper, Roland Penzel, Christoph Heining, (unknown), Thorsten Zenz, Andreas von Deimling, Peter Schirmacher, Anthony D. Ho, Hartmut Goldschmidt, Kai Neben, Marc S. Raab	171
10	Prognostic or predictive value of MGMT promoter methylation in gliomas depends on IDH1 mutation 2013 ·Neurology ·Wolfgang Wick, Christoph Meisner, Bettina Hentschel, Michael Platten, (unknown), Benedikt Wiestler, Michael Sabel, Susanne Koeppen, Ralf Ketter, Markus Weiler, Ghazaleh Tabatabai, Andreas von Deimling, Dorothee Gramatzki, Manfred Westphal, Gabriele Schackert, Markus Loeffler, Matthias Simon, Guido Reifenberger, Michael Weller	173
11	Long-Term Survival in Primary Glioblastoma With Versus Without Isocitrate Dehydrogenase Mutations 2013 ·Clinical Cancer Research ·Christian Hartmann, Bettina Hentschel, Matthias Simon, Manfred Westphal, Gabriele Schackert, Jörg C. Tonn, Markus Loeffler, Guido Reifenberger, Torsten Pietsch, Andreas von Deimling, Michael Weller, (unknown)	138
12	Effector T-Cell Infiltration Positively Impacts Survival of Glioblastoma Patients and Is Impaired by Tumor-Derived TGF-β 2011 ·Clinical Cancer Research ·Jennifer Lohr, (unknown), Andrea Huppertz, Yingzi Ge, Christine Dictus, Rezvan Ahmadi, Stefan Grau, Nobuyoshi Hiraoka, Volker Eckstein, Rupert Ecker, Thomas Korff, Andreas von Deimling, Andreas Unterberg, Philipp Beckhove, Christel Herold‐Mende	272
13	Adult Medulloblastoma Comprises Three Major Molecular Variants 2011 ·Journal of Clinical Oncology ·Marc Remke, Thomas Hielscher, Paul A. Northcott, Hendrik Witt, Marina Ryzhova, Andrea Wittmann, Axel Benner, Andreas von Deimling, Wolfram Scheurlen, Arie Perry, Sidney Croul, Andreas E. Kulozik, Peter Lichter, Michael D. Taylor, Stefan M. Pfister, Andrey Korshunov	160
14	HDAC5 and HDAC9 in Medulloblastoma: Novel Markers for Risk Stratification and Role in Tumor Cell Growth 2010 ·Clinical Cancer Research ·Till Milde, Ina Oehme, Andrey Korshunov, Annette Kopp‐Schneider, Marc Remke, Paul A. Northcott, Hedwig E. Deubzer, Marco Lodrini, Michael D. Taylor, Andreas von Deimling, Stefan M. Pfister, Olaf Witt	158
15	Role of LIM and SH3 Protein 1 (LASP1) in the Metastatic Dissemination of Medulloblastoma 2010 ·Cancer Research ·Christopher Traenka, Marc Remke, Andrey Korshunov, Sebastian Bender, Thomas Hielscher, Paul A. Northcott, Hendrik Witt, Marina Ryzhova, Jörg Felsberg, Axel Benner, (unknown), Wolfram Scheurlen, Thomas G. P. Grünewald, Andreas von Deimling, Andreas E. Kulozik, Guido Reifenberger, Michael D. Taylor, Peter Lichter, Elke Butt, Stefan M. Pfister	55
16	Epigenetic Silencing of Death Receptor 4 Mediates Tumor Necrosis Factor–Related Apoptosis-Inducing Ligand Resistance in Gliomas 2009 ·Clinical Cancer Research ·(unknown), Markus D. Siegelin, (unknown), Andreas von Deimling, Ulrike Laß, Bernhard Korn, Wolf Mueller	41
17	Molecular Predictors of Progression-Free and Overall Survival in Patients With Newly Diagnosed Glioblastoma: A Prospective Translational Study of the German Glioma Network 2009 ·Journal of Clinical Oncology ·Michael Weller, Jörg Felsberg, Christian Hartmann, Hilmar Berger, Joachim P. Steinbach, Johannes Schramm, Manfred Westphal, Gabriele Schackert, Matthias Simon, Jörg C. Tonn, Oliver Heese, Dietmar Krex, Guido Nikkhah, Torsten Pietsch, Otmar D. Wiestler, Guido Reifenberger, Andreas von Deimling, Markus Loeffler	476
18	Reversal of P-glycoprotein–Mediated Multidrug Resistance by the Murine Double Minute 2 Antagonist Nutlin-3 2009 ·Cancer Research ·Martin Michaelis, Florian Rothweiler, (unknown), Andreas von Deimling, Kristoffer Weber, Boris Fehse, Bernd Kammerer, Hans Wilhelm Doerr, Jindřich Činátl	83
19	NOA-04 Randomized Phase III Trial of Sequential Radiochemotherapy of Anaplastic Glioma With Procarbazine, Lomustine, and Vincristine or Temozolomide breakdown → 2009 ·Journal of Clinical Oncology ·Wolfgang Wick, Christian Hartmann, Corinna Engel, Mandy Stoffels, Jörg Felsberg, Florian Stockhammer, Michael Sabel, Susanne Koeppen, Ralf Ketter, Richard Meyermann, Marion Rapp, C Meisner, Rolf D. Kortmann, Torsten Pietsch, Otmar D. Wiestler, Ulrike Ernemann, Michael Bamberg, Guido Reifenberger, Andreas von Deimling, Michael Weller	571
20	Histone Deacetylase 8 in Neuroblastoma Tumorigenesis 2008 ·Clinical Cancer Research ·Ina Oehme, Hedwig E. Deubzer, Dennis Wegener, Diana Pickert, (unknown), Barbara Hero, Annette Kopp‐Schneider, Frank Westermann, Scott M. Ulrich, Andreas von Deimling, Matthias Fischer, Olaf Witt	320

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact